339 results about "Anti coagulation" patented technology

The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

A system for minimizing and / or eliminating coagulative or mineral deposits on respective blood-contacting surfaces of implanted medical devices includes an implantable system having a current generating device that is electrically coupled to at least first and second electrodes for developing a current therebetween. The at least first and second electrodes are disposed across a patient's thoracic cavity in a manner so that a particular implanted medical device having at least a portion thereof that is fabricated from an electrically conductive material is disposed in a path substantially between such electrodes, thereby focusing the generated electrical current at the electrically conductive portion of the implanted medical device for therapeutic treatment thereat.

An electronic anti-coagulation stent structure is disclosed. The stent structure comprises a pair of coaxial metal stents having a layer of dielectric material between the stents. A battery is operatively connected preferably near or adjacent to the upstream end upon deployment of the stent. The positive battery terminal establishes an electrical connection to the outer metal stent and the negative terminal establishes an electrical connection to the inner metal stent and this exhibits a capacitor-like properties. The inner metal stent, being negatively charged, promotes a platelet repellent, anti-thrombotic effect.

Aiming at the conditions that heparin has severe bleeding side effects in clinical practice and clinical application thereof is restricted, the invention discloses a technique for producing ultra-low molecular heparin sodium (calcium). The technique comprises the following steps of: taking heparin sodium solution, adding sodium nitrite solution for cracking; adjusting the lysis buffer by using alkaline; absorbing impurities by using an anion-exchange column; washing for obtaining ultra-low molecular heparin calcium; carrying out filtration by using an ultrafiltration membrane and obtaining a precipitate by using alcohol; and after desalting, dehydration, re-precipitation, cooling and drying, obtaining a finished product of ultra-low molecular heparin calcium. The product has better and safer antithrombotic effect under low level of anticoagulation, and can be widely used for preventing and treating diseases such as deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, and the like.

The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.

The invention discloses a small-caliber silk fibroin tubular material and a preparation method thereof and belongs to the field of biomedical materials. The tubular material consists of three layers of materials which are firmly jointed, wherein an outer layer is a tubular electrostatic spinning silk net; a middle layer is a netlike pipe formed by weaving bright silk prepared from degummed silk; and an inner layer is a silk porous material. After the processes of soaking, drying, curing and the like in silk solution, the three layers of the material are firmly jointed, and the inner layer is treated by using anti-coagulation medicaments such as heparin and the like so that the material has coagulation resistance; and the tubular material obtained by using a forming die consisting of a cylindrical intermediate (1), a hollow cylinder (2) and a round base (3) has the inner diameter of between 1 and 8 millimeters, the thickness of between 0.2 and 2 millimeters, high mechanical property, biocompatibility, coagulation resistance and capability of repairing tissues such as blood vessels, nerves and the like.

Novel polypeptides or derivatives comprising the factor VIIIa binding site on factor IXa are disclosed. The novel polypeptides or derivatives have anti-coagulation activity. Nucleic acids encoding those polypeptides are also disclosed. Methods for identifying an agent having anti-coagulation activity are also disclosed. These methods comprise determining whether the agent displaces the polypeptide or derivative from its factor VIIa binding site. The agent identified in these methods is also useful in methods for treating a patient to prevent thrombosis. The treatment methods comprise administration of the agent to the patient. Additional methods are also disclosed for treating a patient to prevent thrombosis, comprising treating the patient with a polypeptide or derivative comprising the factor VIIIa binding site on factor IXa. Methods of preventing coagulation in a blood sample are also disclosed, comprising adding the polypeptides or derivatives described above to the blood sample. Methods of detecting factor VIIIa in a sample are also disclosed. Those methods comprise contacting the sample with the above-described polypeptide or derivative, wherein the polypeptide or derivative also comprises a covalently attached detectable moiety, then determining whether the polypeptide or derivative is binding factor VIIIa from the sample.

The invention relates to a medical apparatus, in particular to an anticoagulant stainless steel coronary support which is made from a high-nitrogen nickel-free austenitic stainless steel material with good blood compatibility. The support is of tubular structure with a mesh surface which is formed by orderly arranging a unit figure on the side surface of a tube along the circumference and axial direction, the primary supporting function is provided by U-shaped corrugated mesh wires extending along the axial direction, the corrugated mesh wires are connected into a whole body by soft mesh wires arranged at intervals, and the diameter of the mesh wire (width or thickness) is 40-100mum; and the surface of the support is passivated and coated with a medication. The anticoagulant stainless steel support has the advantages of good mechanical properties, good flexibility and good anticoagulant property, and can be used as a support for cardiovascular and cerebrovascular systems or a support for other cavity bodies.

An information management, analysis and response generation system is used with monitoring devices for the remote testing and monitoring of system users' physiological information (e.g. diabetes testing, blood pressure testing, anti-coagulation, etc.). The information management, analysis and response generation system allows testing and monitoring devices manufactured by third party companies to communicate with the system through existing communication networks means enabled by proprietary technology. Upon analysis of the collected data, the system is capable of initiating communications with third parties, including interactive clinical alert notifications.

The invention relates to an artificial blood vessel and a preparation method thereof and belongs to the technical field of organ preparing and biological materials. The artificial blood vessel comprises an outer cortex layer, a fibroblast layer, a smooth muscle cell layer, an endothelial cell layer and an inner cavity. The orderly distribution of the endothelial cell layer, the smooth muscle cell layer, the fibroblast layer and the outer cortex layer in the three-dimensional space is achieved through the comprehensive technology of plasma spraying, electric spraying, electrospinning, reverse molding and 3D printing, the anti-coagulation performance of the artificial blood vessel is enhanced through anti-coagulation factors, step-by-step induced differentiation of stem cells in the artificial blood vessel is achieved through a growth factor controlled-release method, the artificial blood vessel is cultured through a pulsation reactor and made to simulate natural animal blood vessels on the structure and the function, and a corresponding substitute is provided for blood vessel transplanting and repairing. The artificial blood vessel is also applicable to other tubular tissue and organs such as the oesophagus, the trachea, the ovarian duct, the bile duct, the urethra and the bladder.

The invention discloses liquid-base cell preservation liquid as well as a preparation method and application thereof, relating to the technical field of biology. The liquid-base cell preservation liquid contains the following components in parts by weight: 12-18 parts of a fixing agent, 2-8 parts of an anti-coagulation agent, 2-10 parts of a buffer agent, 0.5-0.8 part of an ion strength maintaining agent, 2-8 parts of an antimicrobial reagent, 0.05-0.2 part of a mucus dissolving agent and 0.1-0.4 part of a cleanser. The liquid-base cell preservation liquid has the advantages that the cell stability is high, cells are well fixed, the cost is low, the preserved cell forms are relatively complete, and the like. Besides, the invention further provides the preparation method of the liquid-basecell preservation liquid and application of the liquid-base cell preservation liquid in human body cast-off cells.

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The invention relates to the technical field of medical equipment for a hematology department, in particular to a blood anti-coagulation shaking device for blood detection. The blood anti-coagulationshaking device comprises a base, a slide frame seat, a swing control slider, a vertical slide control slider and a test tube placement box. The blood anti-coagulation shaking device has the advantagesthat while the left and right shaking is performed, the up and down shaking and the front and back swing are also performed, and the blood in a blood sampling bottle is shaken in a multi-dimensionalway, so that the artificial shaking of the blood sampling bottle by hands is replaced, the influence to the detection progress due to nonuniform mixing caused by gelled blood formed by blood coagulation is avoided, the accuracy of detection results is guaranteed, and the labor intensity of medical staff is decreased; the slide frame seat is glidingly connected with the base, the swing control slider is glidingly connected with the left end of the slide frame seat, and the vertical slide control slider is glidingly connected with the right end of the slide frame seat, and is engaged with the slide frame seat in a slide connection way; the test tube placement box is fixedly connected between the swing control slider and the vertical slide control slider.

The present invention relates to a compound medicine for preventing and curing angiocardiopathy and cerebrovascular disease, belonging to the field of chemical medicine. It is characterized by that said compound medicine includes sexual hormones medicine, lipid-reducing medicine, hypotenser, hypoglycemic medicine and anticoagulant medicine. Said compound medicine can be made into various dosage forms. Besides, said compound medicine also can be used for curing the diseases of climacteric syndrome, osteoporosis, endometrial carcinoma, diabetes and metabolic syndrome, etc.

The invention discloses a preparation method of holozoic sea cucumber biological wine, characterized in that the method comprises the steps of: firstly soaking dry sea cucumber in warm water, filtering the sea cucumber, and leaching the aqueous solution to obtain sea cucumber soaking solution; cutting the soaked sea cucumber along the abdomen, clearing the internal organs and the limestone, flushing the sea cucumber through running water, and crushing the sea cucumber to obtain sea cucumber powder; and then, adding the sea cucumber powder in the sea cucumber soaking solution, adding neutral protease, stirring, regulating the pH to 7-8, heating to 45-48 DEG C, hydrolyzing at a constant temperature for 12-18 h, filtering, heating the filtrate to 80-90 DEG C, deactivating enzyme for 10-15 min, cooling, adding sugar substrate, common fermenting for 2-16 weeks, modulating through Chinese medicinal herb leaking solution and filtering to obtain the finished product. The prepared wine contains sea cucumber characteristic ingredients such as sea cucumber polysaccharide sulfate, sea cucumber saponin, sea cucumber amino acid and sea cucumber collagen peptide, and the wine has the functions of anti-tumor, immunity improvement, anti-coagulation, anti- thrombus, anti-radiation, anti-virus, liver protection and blood vessel protection.

The invention relates to a preparation of anti-coagulation dermis scaffold which is used for skin injury repair and has good three-dimensional porous structure. The scaffold preparation uses three natural biologicals of regeneration silk fibroin, chitosan and heparin as raw materials, wherein, heparin has outstanding anti-coagulation property. The dermis scaffold has high porosity and aperture size appropriate for dermal cells to grow; the scaffold has better mechanical property and good hydrophily; the artificial dermis scaffold has heparin slow release function, so that the protrombin time, partial thromboplastin time and thrombin time thereof can be obviously prolonged, thus proving that the dermis scaffold has excellent anti-coagulation property.

The present invention relates to antibiotic dressing for treating injury of mammal, especially human body, and is especially a kind anti-coagulation nano silver antibiotic dressing prepared via anti-coagulation technology. The antibiotic dressing includes a kind of fabric and composite nano silver particles deposited onto the fabric, and the composite nano silver particles in the size of 1-100 nm are attached firmly between the fiber elements and on the fiber. The composite particles have core of metal silver and surface layer of silver oxide, which accounts for 10-80 wt% of the whole composite particles, and the silver content of the dressing is less than 50 microgram each squared millimeter.

The invention relates to an occluder for occluding a left aurcle. The novel left aurcle occluder comprises a left aurcle packing column of the occluder, upper barbs of the left aurcle packing column of the occluder, a fixed steering connecting device, a left aurcle cover plate of the occluder, a blood flow barrier membrane, and the like. The novel left aurcle occluder is implanted into the human body by utilizing a minimally invasive therapy method and used for preventing the forming of a thrombus in the left aurcle of a patient with atrial fibrillation by occluding the left aurcle, so that the risk that long-term disability or death due to thromboembolism happens to the patient with atrial fibrillation is lowered. Meanwhile, long-term dependence of the patient with atrial fibrillation on anticoagulant drugs can be eliminated by occluding the left aurcle to provide a new treatment choice for the patient. The occluder is woven by nickel-titanium alloy wires, has a preset extensional appearance, and is used for connecting the left aurcle packing column of the occluder with the left aurcle cover plate of the occluder by virtue of the fixed steering connecting device; the upper barbs of the left aurcle packing column of the occluder are woven on the left aurcle packing column, and the blood flow barrier membrane is sewn in the left aurcle cover plate of the occluder. The novel left aurcle occluder can be used for occluding and blocking the blood flow from entering the left aurcle, the whole left aurcle occluder is smooth and flat in surface and beneficial to epithelization after being implanted.

The invention takes diazo-resin or multivalence metal ion solution as cross-linking agent. Through the electrostatic attraction LBL self-assembly technology, overstable endovascular stent graft anti-coagulation coating is prepared to lead the anti-coagulation coating to have good blood compatibility and tissue compatibility. The invention is realized in the following steps: a, the surface of an endovascular stent graft is cleaned, firstly, the surface of the endovascular stent graft is ultrasonically cleaned with multiple organic solvents for 1 to 120 minutes, and then the surface thereof is rinsed to be clean with water; b, oxidation treatment: H2O2 is boiled for 1 to 120 minutes, and then is rinsed with fresh water, KOH solution is etched for 1 to 120 minutes and then flushed to be clean with a large amount of fresh water; c, the preparation of the anti-coagulation coating: the diazo-resin with positive electricity and a polymer with anti-coagulation reactivity and / or the other polyanion solution are alternately deposited on the surface of the material through the electrostatic attraction function, ultraviolet light or visible light is adopted to irradiate surface coating of the material, through the photochemical reaction, ionic linkage between the inner layers of the coating is converted into covalent linkage, so as to attain the overstable anti-coagulation coating; or multivalence metal positive ion and the polymer or polyanion with anti-coagulation reactivity are alternately deposited on the surface of the stent graft material through the electrostatic attraction function, so as to attain the stable anti-coagulation coating.

Methods and apparatus are disclosed for determining new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The inventive methods and apparatus provide an International Normalization Ratio (INR) based on a coagulation reaction with a blood sample of a living being. Embodiments include methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or an ISI, and may be carried out with the patient sample and a coagulation reagent, where the coagulation reagent may be selected from a number of coagulation reagents. One embodiment provides an INRs value which is determined from a prothrombin time (PT or T1) of a patient blood sample and a theoretical end of test time (TEOT), where a theoretical clotting area is used to determine the INRs value according to the expression, INRs=T1*TEOT*MUL, where MUL is a multiplier that takes into account pixel parity and sampling times. The INRs may be used to determine a course of treatment for a patient or other living being without regard to the specific coagulation regent used to generate the coagulation data (e.g., time and optical activity values).

The invention relates to a method for brewing wine by using wormwood, which comprises the following steps: (1) taking 100 parts of glutinous rice by mass, placing in water for soaking for 4-8 hours, scooping up the glutinous rice, cooking, spreading for cooling till 20-28 DEG C, adding 0.5-0.6 part of syeast by mass, evenly stirring and placing into a container; (2) adding 5-10 parts of pure rice wine of 50 degrees by mass after carrying out fermentation of the cooked glutinous rice for 12-20 hours, evenly stirring, squeezing after 100-200 days of sealed fermentation and obtaining juice; (3) taking 0.5-2.5 parts of dry wormwood by mass, adding into 5-10 parts of pure rice wine of 35 degrees by mass for leaching for 3-5 hours and obtaining leaching solution; and (4) mixing the juice with the leaching solution, then heating to 80-90 DEG C, keeping the temperature to 6-8 hours, cooking, removing the wormwood, filtering and obtaining the wine. The wine prepared by the invention has stable wine quality, mellow taste, fragrance and rich nutrition and is rich in amino acids, vitamins and the like, and the wine brewed by the wormwood has the effects of dredging meridians, promoting blood circulation, stopping bleeding, anti-coagulation, anti-bacteria, anti-virus and enhancing immunity.

The invention discloses a blood purification membrane with an anticoagulant property and a preparation method thereof. The blood purification membrane comprises a matrix, a polydopamine layer attachedto the surface of the substrate, argatroban grafted on the polydopamine layer and glutathione. The whole surface modification process is simple in experimental conditions, has strong controllability,and is economical and environmentally-friendly; the high-efficiency anti-coagulation on the local part of a material is realized; the blood coagulation system of a body is not affected; the blood compatibility is significantly improved; and the grafted anticoagulant drug argatroban has no antigenicity and does not cause heparin-induced thrombocytopenia.

The invention relates to a preparation method of an anti-coagulation hemodialysis membrane. The preparation method includes the steps of: a) adding acrylonitrile and ethyl methacrylate into a reaction kettle according to mass ratio of 0.1-5.5:1, stirring the mixture and dropwise adding a polymerization initiator to initiate free radical polymerization to obtain an acrylonitrile-ethyl methacrylate copolymer; b) blending 1-5.5% of the acrylonitrile-ethyl methacrylate copolymer, 12-18% of polysulfone, 1-12% of an additive, and 65-85% of a solvent to prepare a membrane solution, and spinning the membrane solution to manufacture hollow-fiber hemodialysis membrane; and c) dissolving an active monomer containing an alkene double bond and a hydrophilic group in deionized water, and adding a cerium ammonium nitrate grafting initiator to prepare a soaking water solution, and soaking the hollow-fiber hemodialysis membrane in the soaking water solution to initiate a grafting reaction of the active monomer on the surface of the hollow-fiber hemodialysis membrane, and cleaning the hollow-fiber hemodialysis membrane. The surface hydrophilicity of the hemodialysis membrane is significantly improved. The hemodialysis membrane has high biocompatibility and anti-coagulation performance.

Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally before or during bypass surgery on diseased coronary, peripheral, and cerebral arteries, surgery to implant grafts or transplanted organs, or angioplasty, or to stabilize unstable plaques. In an alternative embodiment, the apolipoprotein is not provided directly, but the gene encoding the apolipoprotein is provided. The gene is introduced into the blood vessel in a manner similar to that used for the protein, where the protein is then expressed. The technique can also be used for delivery of genes for treatment or prevention or restenosis or other cardiovascular diseases. In yet another embodiment, stents are coated with apolipoproteins alone, apolipoproteins formulated with lipids, genetically engineered cells expressing the apolipoproteins, naked DNA coding for an apolipoprotein, or other drugs such as anti-proliferatives for local delivery to an injury site. In a preferred embodiment, the system is used with combination therapy, with for local delivery of an agent such as an apolipoprotein in combination with systemic anti-hypertension therapy, anti-inflammatoy therapy, lipid regulation and / or anti-coagulation therapy. These treatments can begin prior to, concurrent with or following local delivery.

The invention relates to a lubricant which is used for high-speed conveyer apron production lines of PET bottles, glass bottles, ring-pull cans and the like and belongs to the filed of chemical lubricant. The proportion of the water-based chain lubricant is that oleic acid triethanolamine 3-8%, triethanolamine 4-9%, LF-131 2-5%, isothiazolin-ketone 1-3%, polymaleic acid 0.5-2%, glucuronidase 4-9%, EDTA-2Na 4-10%, benzotriazole 0.5-2%, sodium sulfonate xylene 0.5-2% and H2O 65-75%, wherein the water-based chain lubricant has high lubricating property and good solubility and is provided with a plurality of excellent performances as anti-hard water, sterilization, low-foam, non-corrosiveness, crack resistance, anti-coagulation and the like, when the lubricant is used in a lubricating system, the bottles inverting ratio can be effectively reduced, the workshop environment can be improved, and the service life of scraping belts cab be prolonged.

This invention relates to a novel form of protein C or activated protein C. More specifically, the invention is directed to a variant of protein C that is activated at a higher rate than wild-type or other variants and produces an activated protein C with reduced anticoagulant properties while retaining the protective anti-inflammatory and anti-apoptotic properties of wild-type activated protein C. This novel APC variant will be beneficial for treating inflammatory and apoptotic disorders with a reduced risk for bleeding.

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.